ArticleESC heart failure2021
Heart failure related to adult congenital heart disease: prevalence, outcome and risk factors.
Article in ESC heart failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05580510 ("An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan in Adult Patients With Chronic Heart Failure With Reduced Ejection Fraction Associated With Congenital Heart Disease"), which is not on this map. Cited by 35 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
"An Open-label Clinical Trial to Evaluate the Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan in Adult Patients With Chronic Heart Failure With Reduced Ejection Fraction Associated With Congenital Heart Disease"
Who cites it
35 citing papers in PubMed, 3 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Prevalence of Pulmonary Hypertension in Individuals With Heart Failure: A Systematic Review and Meta-Analysis.Clinical cardiology · 2025Pooled it
- A Systematic Review and Meta-Analysis of the Safety and Efficacy of SGLT2 Inhibitors in Chronic Heart Failure in ACHD Patients.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Pooled it
- The efficacy of the treat-repair-treat strategy for severe pulmonary arterial hypertension associated with congenital heart disease: a meta-analysis.BMC cardiovascular disorders · 2023Pooled it
- Clinical worsening in adult congenital heart disease and heart failure: A single-centre, observational study.International journal of cardiology. Congenital heart disease · 2026Article
- Artificial Intelligence-Enabled ECG for Diastolic Dysfunction in Congenital Heart Disease: A Novel Risk Stratification Tool.JACC. Advances · 2026Article
- Real-world experience with sodium-glucose cotransporter 2 inhibitors in adults with Fontan circulatory failure.Frontiers in cardiovascular medicine · 2026Article
- Expanding the scope of SGLT inhibitors in underrepresented cardiac populations: from pathophysiology to clinical evidence.Frontiers in cardiovascular medicine · 2026Review
- Recent advances in congenital heart disease with a systemic right ventricle: new insights for heart failure treatment from last EURO-ACHD Congress 2025.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Heart failure in patients with a systemic right ventricle: A multicentre study with long-term follow-up.European journal of heart failure · 2025Article
- Echocardiographic effects of sodium-glucose cotransporter 2 inhibitors in single ventricle circulatory failure.International journal of cardiology. Congenital heart disease · 2025Article
- Effect of sodium-glucose cotransporter 2 inhibitors on ventricular function in systemic right ventricular failure.Open heart · 2025Article
- Overweight and Obesity in Adults with Congenital Heart Disease and Heart Failure: Real-World Evidence from the PATHFINDER-CHD Registry.Journal of clinical medicine · 2025Article
- A noninvasive method for determining elastic parameters of valve tissue using physics-informed neural networks.Acta biomaterialia · 2025Article
- Dietary inflammation and its impact on congestive heart failure in older adults with depression.Scientific reports · 2025Article
- Article
- Supraventricular Tachycardia in A Young Adult with Congenital Heart Disease: Successful Ablation after Patent Ductus Arteriosus Closure.European journal of case reports in internal medicine · 2025Article
- Impact of guideline directed medical therapy on myocardial function in adults with congenital heart disease.International journal of cardiology · 2024Article
- Article
- Medical Therapy for Heart Failure in Adult Congenital Heart Disease Patients.Structural heart : the journal of the Heart Team · 2024Review
- Impact of heart failure on reoperation in adult congenital heart disease: An innovative machine learning model.The Journal of thoracic and cardiovascular surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsInformation on the prevalence, outcome and factors associated with heart failure in patients with adult congenital heart disease (CHD) (ACHD-HF) is lacking. We aimed at assessing the prevalence and outcome of ACHD-HF, the variables associated with ACHD-HF, and the differences between major anatomical/pathophysiological ACHD subgroups. METHODS AND
resultsWe included 3905 patients (age 35.4 ± 13.2 years) under active follow-up in our institution (last visit >2010). Outcome of ACHD-HF cases was compared with sex- and age-matched cases. Univariable and multivariable binary logistic regression with ACHD-HF diagnosis as a dependent variable was performed. Overall prevalence of ACHD-HF was 6.4% (mean age 49.5 ± 16.7 years), but was higher in patients with cyanotic CHD (41%), Fontan circulation (30%), and a systemic right ventricle (25%). All-cause mortality was higher in ACHD-HF cases when compared with controls (mortality rate ratio 4.67 (2.36-9.27); P = 0.0001). In multivariable logistic regression analysis, age at latest follow-up [per 10 years; odds ratio (OR) 1.52; 95% confidence interval (CI) 1.31-1.77], infective endocarditis (OR 4.11; 95%CI 1.80-9.38), history of atrial arrhythmia (OR 3.52; 95%CI 2.17-5.74), pacemaker implantation (OR 2.66; 95% CI 1.50-4.72), end-organ dysfunction (OR 2.41; 95% CI 1.03-5.63), New York Heart Association class (OR 9.28; 95% CI 6.04-14.25), heart rate (per 10 bpm; OR 1.27; 95% CI 1.08-1.50), ventricular dysfunction (OR 3.62; 95% CI 2.54-5.17), and pulmonary hypertension severity (OR 1.66; 95% CI 1.21-2.30) were independently related to the presence of ACHD-HF. Some variables (age, atrial arrhythmia, pacemaker, New York Heart Association, and ventricular dysfunction) were related to ACHD-HF in all anatomical/physiological subgroups, whereas others were not.
conclusionsACHD-HF is prevalent especially in complex CHD and is associated with poor prognosis. Our data provide insight in the factors related to ACHD-HF including differences between specific anatomical and physiological subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.